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epsis, Calcineurin,
nd Cardiac Dysfunction
he Saga of Life and Death*
abine Telemaque, PHD,†
awahar L. Mehta, MD, PHD, FACC†‡
ittle Rock, Arkansas
rogrammed cell death, or apoptosis, is a multifactorial
vent that can be triggered by an array of pathophysiological
onditions. The cellular mechanisms by which myocardial
poptosis occurs in response to stress-induced and/or
eurocrine-mediated signaling pathways are quite complex.
hese have been the focus of numerous investigations over
he past decade (1). Important conditions associated with
ardiac myocyte apoptosis include ischemia-reperfusion (2),
eart failure (3), and sepsis (4).
See page 491
Exposure of heart to lipopolysaccharide (LPS), as hap-
ens in patients with sepsis, activates a myriad of cellular
vents. The adverse effect of LPS on cardiac function has
een known for many years. Yang et al. (5) reported that left
entricular function was reduced after administration of
PS, and postulated that the activation of nitric oxide
ynthase (iNOS) and release of large amounts of nitric oxide
NO) in response to LPS was responsible for diminished
ardiac pump function. Along the same line of thought, Li
t al. (4) showed that activation of iNOS and subsequent
yclic guanosine monophosphate (cGMP) accumulation,
nd activation of local renin-angiotensin system led to
yocyte injury resulting in cardiac dysfunction. Yasuda and
ew (6) reported that exposure of cardiac myocytes to LPS
ecreased cell shortening with no change in calcium tran-
ients, indicating decreased myofilament responsiveness to
alcium. They demonstrated that these effects were medi-
ted in large part via NO-cGMP–mediated mechanisms.
In this issue of the Journal, Suzuki et al. (7) describe a novel
ellular mechanism by which LPS induces apoptosis in rat
ardiac myocytes. After exposure to LPS, these investigators
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Division of Cardiovascular Medicine, Department of Medicine,o
niversity of Arkansas for Medical Sciences, and the ‡Central Arkansas Veterans
ealthcare System, Little Rock, Arkansas.eport that calcineurin, a central regulator of calcium-mediated
ignals, is activated in cardiac myocytes and leads to apoptosis.
alcineurin, also known as protein phosphatase 2B, is a
biquitous calcium-sensitive protein phosphatase composed of
catalytic and a regulatory subunit. Calcineurin is a major
articipant in the development, cellular regulation of calcium
omeostasis, and intracellular trafficking in most mammalian
issues (8). The role of the calcineurin as a mediator of
athological hypertrophy has been largely established (9). In
he myocardium, calcineurin is a central pro-hypertrophic
ignaling molecule (10). The catalytic beta-isoform of cal-
ineurin is up-regulated in the cardiac myocytes in response to
ypertrophic stimulus (11). Various genetic approaches have
upported the importance of the calcineurin signaling pathway
n the regulation of cardiac growth (12). De Windt et al. (13)
ave also shown that calcineurin-mediated hypertrophy pro-
ects cardiac myocytes from apoptosis, both in vivo and in vitro.
While it is possible and likely that the failing heart
evelops apoptosis in late stages, the description of apopto-
is due to calcineurin activation soon after exposure of
ardiomyocytes to LPS in vitro by Suzuki et al. (7) remains
ntriguing. Importantly, this group previously showed that
ngiotensin II, a product of renin-angiotensin system acti-
ation increased apoptosis in cardiac myocytes, and the
ffect of angiotensin II was blocked by losartan. Angiotensin
I is synthesized by cardiac myocytes and can lead to
poptosis and hypertrophy of cardiomyocytes (14).
It is quite possible that cell growth and apoptosis go hand in
and, and the preponderance of hypertrophy or apoptosis
epends upon the stimulus, duration of exposure to the
timulus, intensity (dose) of the stimulus, and environment in
hich cardiac myocytes are going through cell cycle.
Suzuki et al. (7) suggest that calcineurin is released after
elease of angiotensin II and its activation. In their studies,
alcineurin-mediated apoptosis was not accentuated by
ngiotensin II, implying that angiotensin II acts proximal to
alcineurin pathway.
They show a dose-dependent increase in calcineurin activity
n response to LPS. Since the number of apoptotic cells
ncreased by 40% simultaneously, and cyclosporin A pre-
ented the pro-apoptotic affects of LPS, it is likely that
alcineurin had a potent effect on cell cycle. The link between
PS, calcineurin, and apoptosis would have been stronger if
hey had provided data on LPS-mediated increase in cal-
ineurin messenger ribonucleic acid (mRNA) and protein.
hile it is possible that calcineurin activity increases without a
hange in mRNA and protein after exposure of cardiac
yocytes to LPS, the pathways leading to calcineurin expres-
ion and activation need to be better defined.
Although cyclosporin A alters the T-cell receptor signal
ransduction pathway via formation of a complex with
yclophilin that inhibits calcineurin, it has also been shown
o inhibit NO synthesis induced by LPS and cytokines (15).
n this context, it may be difficult to determine if the effects
f cyclosporin A treatment on apoptosis are distinct from a
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January 30, 2007:500–1 Editorial Commentirect action on calcineurin or if other factors also contribute
o this inhibition.
While the authors’ work has some novelty, further work
eeds to be done before the paradigm of the effect of LPS
n cardiac myocyte apoptosis being mediated by calcineurin
ctivation can be fully accepted. As the authors point out,
hese findings do not prove that calcineurin activation is
equired for LPS-induced apoptosis. Moreover, studies are
eeded to elucidate the downstream signaling pathways that
re triggered after LPS-induced calcineurin activation.
Calcineurin activation in response to LPS described in
his issue of the Journal expands the paradigm of organ
reservation during injury. It remains to be determined
hether calcineurin temporally regulates only the patholog-
cal development of hypertrophy, or whether it is also
nvolved in the cellular mechanisms leading to cell death.
Apoptosis is an important mechanism of cell survival,
eplication, and death. The mechanisms involved in its
enesis are far from clear. While a number of investigators
ave shown that apoptosis can be prevented, to the best of
ur knowledge no one has shown that program of cell death
hile in motion can be undone.
eprint requests and correspondence: Dr. Jawahar L. Mehta,
ivision of Cardiovascular Medicine, University of Arkansas for
edical Sciences, 4301 West Markham Street, Mail Slot 532,
ittle Rock, Arkansas 72205. E-mail: MehtaJL@uams.edu.
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